Moldova - rumunų - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

egis pharmaceuticals plc - levomepromazinum - comprimate filmate - 25 mg

Europos Sąjunga - rumunų - EMA (European Medicines Agency)

pacira limited - citarabină - meningeal neoplasme - agenți antineoplazici - tratamentul intrathecal al meningitei limfomatoase. În majoritatea pacienților, un astfel de tratament va face parte din paliația simptomatică a bolii.

Rumunija - rumunų - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

santen oy - finlanda - tafluprostum - pic. oft., sol. - 15micrograme/ml - antiglaucomatoase si miotice analogi de prostaglandine

Moldova - rumunų - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

actavis group ptc ehf. - sumatriptanum - comprimate filmate - 100 mg

Moldova - rumunų - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

actavis group ptc ehf. - sumatriptanum - comprimate filmate - 50 mg

Moldova - rumunų - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

compania naţională de cercetări s.r.l. - extract de cartof - soluţie injectabilă - 0,04 mg/ml

Rumunija - rumunų - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

berlin chemie ag - germania - bilastinum - sol. orala - 2,5 mg/ml - antihistaminice de uz sistemic alte antihistaminice de uz sistemic

Moldova - rumunų - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

alembic pharmaceuticals limited - telmisartanum + hydrochlorothiazidum - comprimate - 40 mg + 12,5 mg

Europos Sąjunga - rumunų - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

Rumunija - rumunų - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zentiva sa - romania - pethidinum - sol. inj. - 50mg/ml - alcaloizi naturali din opiu derivati de fenilpiperidina